Description
Gemcitabin Medak Powder for Infusions 1500 mg Vial №1
Ingredients:
Gemcitabine hydrochloride
Mechanism of Action:
Gemcitabine, the active ingredient in Gemcitabin Medak, is a nucleoside analog that disrupts DNA synthesis in cancer cells, leading to cell death. By inhibiting ribonucleotide reductase, gemcitabine prevents the production of deoxynucleotides necessary for DNA replication, thereby exerting its cytotoxic effects on rapidly dividing cancer cells.
Pharmacological Properties:
Gemcitabine exhibits antineoplastic activity by targeting and inhibiting key enzymes involved in DNA replication. It is a prodrug that undergoes intracellular phosphorylation to form active nucleotide metabolites, which interfere with DNA synthesis and induce apoptosis in cancer cells.
Indications for Use:
Gemcitabin Medak is indicated for the treatment of various malignancies, including pancreatic cancer, non-small cell lung cancer, and metastatic breast cancer. It is prescribed for both initial therapy and as part of combination regimens for advanced or metastatic disease.
Contraindications:
Do not use Gemcitabin Medak if you have a known hypersensitivity to gemcitabine or any components of the formulation. Patients with severe renal impairment or compromised bone marrow function should also avoid this medication due to the increased risk of adverse reactions.
Side Effects:
Common side effects of Gemcitabin Medak include nausea, vomiting, myelosuppression (e.g., neutropenia, thrombocytopenia), fatigue, and flu-like symptoms. Infusion-related reactions and peripheral edema may also occur. Regular monitoring of blood counts and renal function is essential during treatment to detect and manage potential adverse effects promptly.
Usage Instructions:
Gemcitabin Medak is administered intravenously under the supervision of a qualified healthcare professional in a specialized clinical setting. The dosage and administration schedule are individualized based on the patient’s overall health status, disease type, and treatment response. Premedication to prevent infusion-related reactions may be recommended.
Benefits Compared to Analogues:
Gemcitabin Medak offers a distinct advantage over traditional chemotherapeutic agents due to its unique mechanism of action and broad-spectrum activity against various solid tumors. Its efficacy in combination regimens has been well-documented, providing enhanced therapeutic outcomes and improved survival rates compared to single-agent therapies.
Suitable Patient Groups:
Gemcitabin Medak can be safely used in adult patients across different age groups, including the elderly population. Dose adjustments may be necessary in individuals with renal impairment or compromised bone marrow function to minimize the risk of hematologic toxicity.
Storage and Shelf Life:
Store Gemcitabin Medak powder for infusions as per the manufacturer’s recommendations, typically at controlled room temperature away from light and moisture. Check the product labeling for specific storage instructions. Do not use the medication beyond the expiration date printed on the packaging.
Packaging Description:
Gemcitabin Medak is supplied as a sterile powder in a single-dose vial containing 1500 mg of gemcitabine hydrochloride. Each vial is for single use only and should be reconstituted with the appropriate diluent before administration. The packaging is designed to maintain product integrity and sterility until the time of use.
